Multi-Compound CNS Therapy With Ultra-Low THC for Amyloid and Tau
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's Disease (AD) and Parkinson's Disease are inadequate, with no cure and significant side effects from high doses of monotherapies targeting specific pathways, and combination therapies have not effectively addressed the complex pathologies of amyloidosis, protein folding, and tauopathy.
Innovation Solution
A combination therapy using ultra-low doses of tetrahydrocannabinol (THC), melatonin, and curcumin, optionally with cannabidiol (CBD), administered orally in a stable liquid carrier, targets multiple pathways to reduce Aβ expression, aggregation, and tau phosphorylation, enhancing mitochondrial function and reducing anxiety and caregiver distress without severe side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of monotherapy targeting specific pathways are used, then therapeutic efficacy is improved, but severe side effects and psychological impairments occur
Solution Approach 1:
The patent combines multiple therapeutic agents (cannabis compounds, melatonin, curcumin) into a single composition that targets multiple pathological pathways simultaneously. This multi-component formulation addresses amyloidosis, protein folding, and tauopathy through synergistic actions, achieving therapeutic efficacy while using lower individual doses to minimize side effects
Solution Approach 2:
The patent employs ultra-low doses of cannabis compounds (THC, CBD) that are significantly lower than conventional therapeutic doses. By changing the dosage parameter to ultra-low levels and combining with other agents, the formulation achieves neuroprotection and symptom management without the severe side effects and psychological impairments associated with high doses
2Adaptability or versatility
If combination therapies targeting multiple pathways are used, then coverage of complex pathologies is improved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple therapeutic agents with different mechanisms of action into a single integrated composition. This includes cannabis compounds for neuroprotection and inflammation modulation, melatonin for oxidative stress reduction and circadian regulation, and curcumin for anti-amyloid and anti-inflammatory effects, all delivered together to address complex CNS disorders
Solution Approach 2:
The composition is designed with multi-functionality to address multiple pathological mechanisms simultaneously. Each component contributes to various aspects of disease pathology (amyloid aggregation, tau phosphorylation, oxidative stress, inflammation), making the formulation universally applicable to different manifestations of Alzheimer's disease and related CNS disorders
Data Source
AI summary
Compositions and methods for treating a range of Central Nervous System (CNS) disorders and diseases such as amyloidosis, protein folding diseases, tauopathy, and specifically Alzheimer's Disease and Parkinson's Disease, among others, in humans and in veterinary animals, by administering to a subject in need thereof a formulation comprising of melatonin, curcumin, and cannabis, specifically THC alone or with CBD.